Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

Background Pathogenic extrafollicular double negative 2 (DN2) B cells in SLE have a phenotype of IgD − CD27 − Tbet + CD11c +, and are the precursor of ribonuclear protein (RNP) autoantibody producing ...

Introduction Double-stranded-DNA antibodies (antiDNAds) are the most frequently detected serological markers in patients with Systemic Lupus Erythematosus (SLE). In clinical practice, it is usually ...

Background/Purpose The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill this knowledge gap by ...

Purpose TLR7 and TLR8 (TLR7/8) are members of the Toll-Like Receptor family that recognize single strand RNA. Activation of TLR7/8 within immune cells elevates pro-inflammatory cytokines and type ...

Background Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease characterized by pathogenic autoantibodies and tissue damage to multiple organ systems. Nipocalimab is a novel ...

Given the need for more effective treatments, there is a pressing need for a better understanding of chronic pain, including pain in SLE. Discovery of peripheral sodium channels (Nav1.7, Nav1.8, ...

In active SLE, CRP levels are disproportionally low for increased IL-6 levels. While a molecular explanation is lacking, these low CRP levels have been found associated with increased type I ...

Systemic lupus erythematosus (SLE) is the most common form of lupus; however, the development of new drugs for SLE has been limited, with only two drugs approved in the past 60 years. Recently, the ...

Chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated efficacy in treating active lupus in both human and mouse lupus. However, a significant limitation of this approach is ...

Objective The Lupus Clinic at University College London Hospital (UCLH) has been recruiting patients since 1979.We carried out a comprehensive study of the records of patients from the clinic to study ...

Background Casein kinase II (CSNK2) is a key regulator of cell activation, proliferation, and apoptosis. While primarily an intracellular molecule, it has recently been appreciated that CSNK2 is ...